<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676349</url>
  </required_header>
  <id_info>
    <org_study_id>2014-005681-29</org_study_id>
    <nct_id>NCT02676349</nct_id>
  </id_info>
  <brief_title>Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)</brief_title>
  <official_title>Two Arm, Prospective, Multicenter Randomized Phase II Trial of Neoadjuvant Modified Folfirinox Regimen, With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, randomized phase II trial. The aim of this study is to assess the
      efficacy of two therapeutics strategies. Patients with borderline-resectable pancreatic
      cancer (BRPC) will be randomly in two arms : neoadjuvant mFolfirinox followed with or without
      preoperative chemoradiotherapy with capecitabine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Surgery, especially if followed by adjuvant chemotherapy, offers the only chance of cure of
      pancreatic cancer. At first diagnosis, after careful assessment, only 10 to 15% of patients
      are considered to be candidates for surgical resection and about 7% have a potentially
      resectable disease. These potentially resectable tumors called &quot;borderline resectable
      pancreatic cancer&quot; (BRPC) are conceptualized as those that involve the mesenteric vasculature
      to a limited extent and those for which resection, while possible, would likely be
      compromised by positive surgical margins (R1) in the absence of neoadjuvant treatment. R0
      resection is indeed considered as an independent prognostic factor for survival when the
      surgical procedures, histological examination and definition of microscopic invasion are
      standardized.

      The objectives of neoadjuvant treatments of BRPC is to reduce tumor volume before surgery in
      order to improve the chances of radical (R0) resection and to reduce the rate of lymph node
      positivity and recurrences. The primary outcome in published studies is usually R0 resection
      rate, but these results also depend on the number of margins examined and the definition of
      microscopic margin involvement. Prospective studies with consistent selection criteria and
      standardized assessment criteria are needed.

      Different neoadjuvant therapeutic strategies have been tested in pilot studies: preoperative
      chemoradiotherapy or neoadjuvant chemotherapy, followed or not by a preoperative
      (chemo)radiotherapy. Due to the lack of randomized studies, the best sequence of treatment
      administration has not been established.

      The aim of this prospective, randomized, multicenter, trial is to evaluate the R0 resection
      rate with neoadjuvant Folfirinox, followed or not by radiochemotherapy for patients with
      borderline resectable pancreatic cancers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the efficacy of two neoadjuvant therapies in patients with borderline resectable pancreatic carcinoma evaluated on histological R0 resection margin rate</measure>
    <time_frame>up to 7.5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the toxicities associated with chemotherapy and chemoradiotherapy</measure>
    <time_frame>up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the proportion of resected patients</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the response rate to chemotherapy and chemoradiotherapy</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the histological complete response rate in resected patients.</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the perioperative mortality rate</measure>
    <time_frame>up to 8.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the perioperative morbidity rate</measure>
    <time_frame>up to 8.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the overall survival</measure>
    <time_frame>up to 7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the quality of life</measure>
    <time_frame>up to 7.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the loco-regional relapse-free survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the metastatic Progression Free Survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the progression-free survival</measure>
    <time_frame>7 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Pancreatic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy with mFolfirinox regimen + concomitant chemoradiotherapy + surgery + adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy with mFolfirinox regimen + surgery + adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFolfirinox</intervention_name>
    <description>oxaliplatin folinic acid irinotecan 5FU oxaliplatin</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Chemoradiotherapy</intervention_name>
    <description>conformational external irradiation (50.4 Gy) + capecitabine</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>surgery</intervention_name>
    <description>1 to 4 weeks after neoadjuvant treatment according to tumour response</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjuvant chemotherapy</intervention_name>
    <description>Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)</description>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ECOG performance status 0 or 1

          -  Adult patients ≥ 18 years and ≤ 75 years of age

          -  Histologic or cytologic proven adenocarcinoma of the pancreas (histologic confirmation
             of diagnosis is preferred)

          -  Confirmation by independent multidisciplinary expert review of borderline resectable
             status, according to NCCN-Clinical Practice Guidelines in Oncology &quot;pancreatic
             adenocarcinoma&quot;, version 1.2015.

          -  Adequate hematologic function, as follows:

          -  absolute neutrophil count (ANC) ≥ &gt; 2000/mm3

          -  platelet count ≥ 100 000/mm3

          -  haemoglobin ≥ 10 g/dL

          -  Adequate renal, hepatic and bone marrow function, defined as:

               -  Calculated creatinine clearance ≥ 50 mL/min according to MDRD formula

               -  Serum total bilirubin ≤ 1.5 times the institutional upper limit of normal.
                  Patients with a biliary short metal stent due to cancer obstruction may be
                  included provided that high-quality imaging is performed before stenting and
                  bilirubin level after stent insertion decreased to ≤ 20 mg/L (≤ 34 µmol/l), and
                  there is no cholangitis.

          -  Male and female subjects who agree to use highly effective methods of birth control
             (e.g., condoms, combined oral contraceptives, some intrauterine devices [IUDs], sexual
             abstinence, or sterilized partner)

               -  for male subject: during the treatment and for up to 6 months after the last dose
                  of oxaliplatin or up to 3 months after the last dose of irinotcan.

               -  for female subject: during the treatment and for up to 4 months after the last
                  dose of oxaliplatin or up to 3 months after the last dose of irinotcan.

          -  Ability to provide written informed consent before the start of any study specific
             procedures

          -  Patient's legal capacity to consent to study participation and to understand and
             comply with the requirements of the study.

        Exclusion Criteria:

          -  Any previous treatment of the pancreatic cancer except biliary short metal stenting
             (chemotherapy, targeted tumor therapy, local ablative therapy, previous irradiation
             within the actual fields of planned radiotherapy)

          -  Evidence of distant metastases including ascites

          -  Evidence of extent of pancreatic cancer beyond that defined as &quot;borderline resectable&quot;
             : suspicious lymphadenopathy outside of the standard field of resection (i.e.,
             aortocaval nodes, distant abdominal nodes)

          -  Contraindication for pancreas resection

          -  Pregnant or breast feeding females

          -  Patients with known Gilbert's Syndrome or homozygosity for UGT1A1*28 polymorphism

          -  Participation in any other clinical trial or treatment with any experimental drug
             within 28 days before enrolment to the study or during study participation until the
             end of treatment visit that can be interfering with the objectives of the study

          -  Previous or concurrent malignant tumor disease other than underlying tumor disease
             (with the exception of cervical cancer in situ, adequately treated non-melanoma skin
             cancers, superficial bladder tumors (Ta, Tis, and T1) or any curatively treated
             without chemotherapy and favourable prognosis tumors without evidence of disease for &gt;
             3 years prior to enrolment)

          -  Any severe and/or uncontrolled medical conditions including but not limited to:

               -  Clinically significant cardiovascular or vascular disease : angina pectoris (even
                  controlled), previous myocardial infarction, serious uncontrolled cardiac
                  arrhythmia, chronic heart failure, acute or chronic infectious disease requiring
                  general treatment)

               -  Acute and chronic, active infectious disorders that requires systemic treatment
                  --- Peripheral polyneuropathy &gt; grade 1

               -  Any previous inflammatory disease of colon or rectum

               -  Any other severe concomitant disease or disorder, which could influence patient's
                  ability to participate in the study and his/her safety during the study e.g.
                  severe hepatic, renal, pulmonary, metabolic, or psychiatric disorders

          -  Hypersensitivity against any of the study drugs (gemcitabine, oxaliplatin, irinotecan,
             5-fluorouracil, folinic acid), or the ingredients of these drugs (e.g. fructose).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thierry CONROY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Baptiste BACHET, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Groupe Hospitalier Pitié Salpêtrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pascal HAMMEL, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Hôpital Beaujon Assistance Publique - Hôpitaux de Paris (AP-HP)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jen Louis MERLIN, Md PharmaD</last_name>
    <phone>03 83 59 83 07</phone>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurinda FERNANDES</last_name>
    <phone>03 83 59 84 87</phone>
    <email>l.fernandes@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BECHADE Dominique, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Polyclinique Bordeaux Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LECAILLE Cédric, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Morvan</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>METGES Jean-Philippe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HAMMEL Pascal, PR</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Colmar</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles Breysacher, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor (APHP)</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BAUMGAERTNER Isabelle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Bicêtre (APHP)</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>THIROT-BIDAULT Anne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier Mirabel, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PIESSEN Guillaume, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital européen Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RINALDI Yves, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DAHAN Laëtitia, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli CALMETTES</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DELPERO Jean-Robert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PORTALES Fabienne, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas REGENET, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CORIAT Romain, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Mutualiste Montsouris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LOUVET Christophe, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pitié Salpêtrière (APHP)</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BACHET Jean-Baptiste, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut-Lévêque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VENDRELY Véronique, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>BOUCHE OLIVIER, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SULPICE Laurent, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chu Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SCHWARZ Lillian</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHP Saint Grégoire</name>
      <address>
        <city>Saint Grégoire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MIGLIANO LAURENT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Saint-Herblain</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>THIBAUDEAU Emilie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>BEN ABDELGHANI Meher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LECOMTE Thierry, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chru Nancy</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AYAV Ahmet</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CONROY Thierry, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mFolfirinox</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Neoadjuvant treatment</keyword>
  <keyword>Borderline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

